Ghazaleh Tabatabai

Professor

Eberhard Karls Universität Tübingen

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Ghazaleh Tabatabai is a faculty member at Eberhard Karls Universität Tübingen, Germany. Her research focuses on targeted therapies and immunotherapy in glioblastoma, exploring innovative treatment approaches such as personalized vaccines and the assessment of clinical benefits in CNS malignancies. She is actively involved in advancing therapeutic strategies for glioblastoma patients through her recent publications.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Vítor Moura Gonçalves

Faculty of Medicine of the University of Porto

PORTUGAL

View details

Leonie Zerweck

University of Tübingen

GERMANY

View details

JIANYING YANG

FRANCE

View details

Reinhild Klein

University of Tuebingen

GERMANY

View details

Matthias Preusser

Medical University

AUSTRIA

View details

Kathrin Machetanz

University of Tübingen

GERMANY

View details

Juliane S. Walz

University Hospital Tübingen

GERMANY

View details

Salvador Castaneda-Vega

GERMANY

View details

Michael Platten

Heidelberg University

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ghazaleh Tabatabai

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lessons ignored?

Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial

Expanding the immunotherapeutic toolbox in glioblastoma: A safe and feasible strategy at the point of surgery

Author Response: MR Spectroscopy in a Patient With Isolated Brainstem Posterior Reversible Encephalopathy Syndrome

Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework

Glioblastom – aktuelle Therapiekonzepte

Correction: Gonçalves et al. Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the Tübingen Schwannoma Cohort. Cancers 2021, 13, 466

Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma

Glioblastom

Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma

Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups

[Diagnosis and therapy of tumors with NTRK gene fusion].

Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the Tübingen Schwannoma Cohort.

H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.

CNS Invasion in Meningioma-How the Intraoperative Assessment Can Improve the Prognostic Evaluation of Tumor Recurrence.

The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy.

Collaborators (9)

Vítor Moura Gonçalves

Leonie Zerweck

JIANYING YANG

Reinhild Klein

Matthias Preusser

Kathrin Machetanz

Juliane S. Walz

Salvador Castaneda-Vega

Michael Platten

Make your next move.